<DOC>
	<DOCNO>NCT03015909</DOCNO>
	<brief_summary>The purpose study ass ease use , preference , safety 8 week subcutaneous administration EutropinPen Inj . patient pretreated recombinant human growth hormone reusable device .</brief_summary>
	<brief_title>Evaluation Ease Use , Preference , Safety EutropinPen Inj .</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Dwarfism , Pituitary</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Turner Syndrome</mesh_term>
	<mesh_term>Gonadal Dysgenesis</mesh_term>
	<mesh_term>Primary Ovarian Insufficiency</mesh_term>
	<mesh_term>Dwarfism</mesh_term>
	<criteria>Subjects use reusable device growth hormone injection recent 3 month least 6 week Subjects meet indication EutropinPen inj . Subjects diseases screen visit Diabetes Malignant tumor Epiphyseal closure Chronic kidney disease ( recieved kidney transplantation ) Acute respitory failure</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>